Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximab
Open Access
- 16 April 2009
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 113 (16), 3809-3812
- https://doi.org/10.1182/blood-2008-10-185280
Abstract
The incorporation of rituximab, a chimeric anti-CD20 monoclonal antibody, into the therapeutic armamentarium for patients with follicular lymphoma (FL) has significantly improved treatment outcome for such patients. Despite the almost universal application of this therapy, however, its exact mechanism of action has not been completely defined. One proposed mechanism is that of a “vaccinal” effect, whereby FL cell kill by rituximab results in the elicitation of an FL-specific T-cell response. The demonstration that rituximab can even elicit such a response in patients has, to our knowledge, never been shown. We analyzed the response against the immunoglobulin expressed by the FL before and after rituximab monotherapy in 5 FL patients and found an increase in FL idiotype–specific T cells after rituximab in 4 of 5 patients. Our data thus provide “proof of principle” for the ability of passive immunotherapy with rituximab to elicit an active FL-specific cellular response.This publication has 26 references indexed in Scilit:
- Immunosuppressive Strategies that are Mediated by Tumor CellsAnnual Review of Immunology, 2007
- Attenuation of CD8+ T-Cell Function by CD4+CD25+ Regulatory T Cells in B-Cell Non-Hodgkin's LymphomaCancer Research, 2006
- Phase II Trial of Idiotype Vaccination in Previously Treated Patients With Indolent Non-Hodgkin’s Lymphoma Resulting in Durable Clinical ResponsesJournal of Clinical Oncology, 2006
- From the bench to the bedside: ways to improve rituximab efficacyBlood, 2004
- Germ line tumor-associated immunoglobulin VH region peptides provoke a tumor-specific immune response without altering the response potential of normal B cellsBlood, 2004
- Inducing Tumor Immunity through the Selective Engagement of Activating Fcγ Receptors on Dendritic CellsThe Journal of Experimental Medicine, 2002
- Mechanism of Cytotoxicity Induced by Chimeric Mouse Human Monoclonal Antibody IDEC-C2B8 in CD20-Expressing Lymphoma Cell LinesCellular Immunology, 2000
- Clustered CD20 Induced Apoptosis: Src-Family Kinase, the Proximal Regulator of Tyrosine Phosphorylation, Calcium Influx, and Caspase 3-Dependent ApoptosisBlood Cells, Molecules, and Diseases, 2000
- Consequences of Cell DeathThe Journal of Experimental Medicine, 2000
- Pro‐inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum‐free conditionsEuropean Journal of Immunology, 1997